Workflow
众生药业:ZSP1601片是具有全新作用机制的治疗代谢功能障碍相关脂肪性肝炎(MASH)的一类创新药

Core Viewpoint - ZSP1601 is an innovative drug targeting metabolic dysfunction-related fatty liver disease (MASH) and is currently in the IIb phase of clinical trials [2] Company Summary - Zhongsheng Pharmaceutical (002317.SZ) confirmed that ZSP1601 is a novel drug with a new mechanism of action [2] - The drug is part of a major national new drug creation project [2]